Table 3.

Adverse events occurring in at least 2 patients in the patiromer group regardless of HF diagnosis during the randomized withdrawal phase and through the safety follow‐up period for that phase^*

	Heart failure		Non‐heart failure
	Placebo (n = 22)	Patiromer (n = 27)	Placebo (n = 30)	Patiromer (n = 28)
≥1 Adverse event	14 (64%)	15 (56%)	12 (40%)	11 (39%)
Headache	3 (14%)	1 (4%)	1 (3%)	1 (4%)
Supraventricular extrasystoles	1 (5%)	1 (4%)	0	1 (4%)
Diarrhoea	0	2 (7%)	0	0
Nausea	0	2 (7%)	0	0
Constipation	0	1 (4%)	0	1 (4%)
≥1 Serious adverse event	1† (5%)	0	0	0

Data are number of patients and percent. HF, heart failure

^*The safety follow‐up period was 1–2 weeks after discontinuation of the study drug.

^†Mesenteric vessel thrombosis leading to death occurred in 1 patient.